Oncolytics Biotech Inc (ONCY)
Oncolytics Biotech develops pelareorep, an experimental intravenous cancer therapy for gastrointestinal tumors. It last closed at $0.38 on Nov 17, up 12.53% on the day.
Key Stats
Fiscal 2024Not reported for this period.
From ONCY's SEC filings, latest 10-Q for the period ending Dec 31, 2024 (filed Nov 13). Figures are in CAD. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 19 | HC Wainwright & Co. | Target lowered | Buy | $10 → $5 |
| May 26 | HC Wainwright & Co. | Reiterated | Buy | $10 |
Technical Analysis
The stock is 11% below its 20 day and 46% below its 50 day average. It is 115% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 38), near oversold. The nearest support is the swing low (Nov 3) at $0.38, and the nearest resistance the Pivot R1 at $0.40.
| RSI (14) | 37.75 | Weak, oversold below 30 | Neutral |
| MACD | -0.05 | Below its signal line | Bearish |
| Stochastic | 20.7 | Middle of its range | Neutral |
| ADX (14) | 44.1 | Strong downtrend | |
| Williams %R | -61.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -103.0 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −1.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.05 | Typical daily range, 12.2% of price |
| RSI (14) | 28.81 | Oversold below 30 | Oversold |
| MACD | -0.13 | Below its signal line | Bearish |
| Stochastic | 8.5 | Near the bottom of its range | Oversold |
| ADX (14) | 21.7 | Weak trend | |
| Williams %R | -91.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -132.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −48.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.12 | Typical daily range, 30.9% of price |
What happened before
See how ONCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ONCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ONCY in the last 90 days.
ONCY Institutional Ownership
Full report →- ▲28 buying vs 24 selling
- ▼Held by funds -0.7 pts
- ▲Funds holding +2
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 77 | 75 | +2.7% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 2.4% | 3.1% | −0.7 pts |
| New / increased | 10 / 18 | 72 / 0 | −61.1% |
| Reduced / sold out | 15 / 9 | 1 / 1 | +1100.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ONCY is in one of them and how their past ONCY trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ONCY in an article yet. Here's the latest on the wider market.
About Oncolytics Biotech
Oncolytics Biotech is a biopharmaceutical company based in San Diego, California. It is developing pelareorep, an experimental cancer therapy given intravenously that is made from a common virus that does not cause disease. The company is testing pelareorep alone and with other cancer treatments, mainly for gastrointestinal cancers, and plans to partner with larger drug companies. Its intended customers are cancer patients and the doctors who treat them.
- Headquarters
- San Diego, CA
- Founded
- 1998
- Website
- oncolyticsbiotech.com ↗


